OVERVIEW

5th Translational Research Conference: Multiple Myeloma is organized by European School of Haematology (ESH).

Event Date: October 08 - 11, 2020

Description:
The plenary E-Conference programme is designed to place emphasis on leading-edge basic and clinical research. The presentation of unpublished data is encouraged. Ample time is deliberately provided for scientific discussion and interaction.

The “Live Programme” is to be found on programme page. It will be streamed live CEST time, as indicated. It will include lectures, roundtable discussions, Meet the Expert sessions, interactive panel discussions, voting and Q&A periods, and Mentored Poster Walks. It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.

The “Programme on Demand” available as of September 29th, 2020, will initially include the pre-recorded components of the scientific programme. It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.

The Virtual platform will remain open from September 29 until October 21, 2020 so that participants can view and review the programme’s full scientific content at times convenient to them.

Topics:
• Smoldering Myeloma
• Diagnosis of Multiple Myeloma
• Frontline therapy in patients not eligible for autologous stem cell transplantation
• Frontline therapy in patients eligible for autologous stem cell transplantation
• MRD and the microenvironment
• Relapsed Multiple Myeloma
• The future: recent clinical trials in relapse
• Data management issues
• Plasma cell disorders

Learning Objectives:
• Update on the pathophysiology of myeloma and how the disease is evolving from MGUS and SMM.
• Update on the diagnostic criteria and the use of new assessments in the diagnostic process
• Treatment of young myeloma patients
• Treatment of elderly and frail myeloma patients
• Optimal sequencing at the relapse
• To know what is the role of new immunotherapic approaches and how will they fit in the landscape
• Role of novel drugs under development
• Latest updates in other plasma cell disorders beyond myeloma